Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

GYRE stock hub

Gyre Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

GYREis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

682.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

GYRE

In the news

Latest news · GYRE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-3.1

P25 -106.6P50 -46.9P75 -3.1

ROIC-17.8

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All GYRE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

195

Groups with data

Currency

USD

Showing 195 of 195 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001124105
Company name	Gyre Therapeutics, Inc.
Country	United States
Country code	US
Cusip	403783103
Employees	625
Employees Change	46%
Employees Change Percent	7.94
Enterprise value	$633.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US4037831033
Last refreshed	2026-05-10
Market cap	$682.5M
Market cap category	Small-Cap
Price	$7.47
Price currency	USD
Rev Per Employee	187,278.4x
Sector	Healthcare
Sic	2834
Symbol	GYRE
Website	https://www.gyretx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.93%
EV Sales Forward	5.91x
EV/EBIT	262.24x
EV/EBITDA	125.93x
EV/Sales	5.41x
P/B ratio	6.73x
P/S ratio	5.83x
PS Forward	6.37x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	2.06%
EBITDA Margin	4.3%
Gross margin	95.09%
Gross Profit	$111.3M
Gross Profit Growth	14.93%
Gross Profit Growth Q	0.6%
Gross Profit Growth3 Y	3.78%
Net Income	$-6.4M
Net Income Growth Years	0%
Pretax Margin	0.48%
Profit Margin	-5.44%
Profit Per Employee	$-10,179
Profitable Years	2
ROA	1.03
ROCE	1.7
ROE	-3.08
ROIC	-17.79

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-15.6%
EPS Growth Years	0
Revenue Growth	16.3x
Revenue Growth Q	2.09x
Revenue Growth Quarters	4x
Revenue Growth Years	1x
Revenue Growth3 Y	3.87x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.8
Assets	$162M
Cash	$49.8M
Current Assets	$91.7M
Current Liabilities	$19.8M
Debt	$823,000
Debt EBITDA	$0.14
Debt Equity	$0.01
Equity	$137M
Liabilities	$25M
Long Term Assets	$70.3M
Long Term Liabilities	$5.2M
Net Cash	$49M
Net Cash By Market Cap	$7.18
Net Cash Growth	73.06%
Net Debt EBITDA	$-9.74
Net Debt Equity	$-0.36
Tangible Book Value	$96.7M
Tangible Book Value Per Share	$1.06
WACC	33.25

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.64
Inventory Turnover	0.6
Net Working Capital	$22.9M
Quick ratio	3.68
Working Capital	$71.9M
Working Capital Turnover	$1.93

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	11.33%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-15.59%
200-day SMA	7.69
50-day SMA	7.56
50-day SMA vs 200-day SMA	50under200
All Time High	30.4
All Time High Change	-75.43%
All Time High Date	2023-12-21
All Time Low	5.88
All Time Low Change	27.04%
All Time Low Date	2023-10-31
ATR	0.38
Beta	5.28
Beta1y	2.15
Beta2y	1.8
Ch YTD	5.81
High	7.47
High52	11.78
High52 Date	2025-05-13
High52ch	-36.59%
Low	7.2
Low52	6.57
Low52 Date	2025-08-01
Low52ch	13.7%
Ma50ch	-1.15%
Price vs 200-day SMA	-2.81%
RSI	47.97
RSI Monthly	48.86
RSI Weekly	47.87
Sharpe ratio	0.07x
Sortino ratio	0.17
Total Return	11.33%
Tr YTD	5.81
Tr1m	4.92%
Tr1w	-4.23%
Tr3m	-5.2%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	1
Analyst Price Target Top	$16
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.07
Earnings Revenue Estimate	32,067,336x
Earnings Revenue Estimate Growth	45.38x
Operating Income	$2.4M
Operating Income Growth	-76.84
Operating Income Growth3 Y	-37.42
Operating margin	2.06
Price target	$17
Price Target Change	$128
Price Target Change Top	$114

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26,901,804%
Float Percent	29.44%
Shares Insiders	6.66%
Shares Institutions	3.68%
Shares Out	91,371,943
Shares Qo Q	0.21%
Shares Yo Y	-11.33%
Short Float	5.89%
Short Ratio	15.05
Short Shares	1.73

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	62,435.2x
Bv Per Share	1.11
Ch1m	4.92
Ch1w	-4.23
Ch1y	-15.59
Ch3m	-5.2
Ch6m	3.61
Change	5.66%
Change From Open	3.61
Close	7.07
Days Gap	1.98
Depreciation Amortization	2,615,000
Dollar Volume	395,170.5
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$2.4M
EBITDA	$5M
EPS	$-0.11
F Score	3
Fiscal Year End	December
Founded	2,002
Income Tax	$4.3M
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-13
Ma150	7.72
Ma150ch	-3.18%
Ma20	7.72
Ma20ch	-3.23%
Next Earnings Date	2026-08-10
Open	7.21
Optionable	Yes
Position In Range	100
Post Close	7.47
Postmarket Change Percent	-4.95
Postmarket Price	$7.1
Ppne	23,572,000
Price Date	2026-05-08
Price EBITDA	$136
Ptbv Ratio	7.06
Relative Volume	0.85x
Revenue	117,049,000x
Tax By Revenue	3.65x
Tax Rate	758.16%
Tr6m	3.61%
Us State	California
Volume	52,901
Z Score	18

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does GYRE pay a dividend?

Capital-return profile for this ticker.

Performance

GYRE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns GYRE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+3.7%

Float: +29.4% of shares outstanding

Insider ownership

+6.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

GYRE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

48.0

Neutral momentum band

Price vs 200-day MA

-2.8%

50/200-day relationship not available

Beta (5Y)

5.28

More volatile than the market

Sharpe ratio

0.07

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About GYRE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current GYRE stock rating?

Gyre Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GYRE analysis?

The full report lives at /stocks/GYRE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for GYRE?

The latest report frames GYRE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the GYRE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.